BioCryst Receives Fast Track Designation For ALK-2 Inhibitor BCX9250
10 June 2022 - 6:18AM
ValueWalk
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a late clinical
stage biotech firm that focuses on oral drugs for the treatment of
rare and serious diseases. The company was founded in 1986 and
first listed on the Nasdaq in 1994. Since listing, BCRX shares have
endured a wild ride of cycles roughly every 5 years. The cyclical
[…]
https://www.valuewalk.com/biocryst-receives-fast-track-designation-for-alk-2-inhibitor-bcx9250/
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2024 to May 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From May 2023 to May 2024